Biblio

Author Title Type [ Year(Desc)]
Filters: Author is Schetelig, Johannes  [Clear All Filters]
2013
Schaich M, Parmentier S, Kramer M, Illmer T, Stölzel F, Röllig C, Thiede C, Hänel M, Schäfer-Eckart K, Aulitzky W, et al. High-Dose Cytarabine Consolidation With or Without Additional Amsacrine and Mitoxantrone in Acute Myeloid Leukemia: Results of the Prospective Randomized AML2003 Trial. J Clin Oncol. 2013.
2014
Middeke JM, Fang M, Cornelissen JJ, Mohr B, Appelbaum FR, Stadler M, Sanz J, Baurmann H, Bug G, Schäfer-Eckart K, et al. Outcome of patients with abnl(17p) acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation. Blood. 2014.
Sommer U, Larsson B, Tuve S, Wehner R, Zimmermann N, Kramer M, Klob A, Günther C, Babatz J, Schmelz R, et al. Proinflammatory human 6-sulfo LacNAc+ dendritic cells accumulate in intestinal acute graft-versus-host disease. Haematologica. 2014.
2015
von Dalowski F, Kramer M, Wermke M, Wehner R, Röllig C, Alakel N, Stölzel F, Parmentier S, Sockel K, Krech M, et al. Mesenchymal Stromal Cells for Treatment of Acute Steroid-Refractory GvHD: Clinical Responses and Long-Term Outcome. Stem Cells. 2015.
Xavier E, Cornillon J, Ruggeri A, Chevallier P, Cornelissen JJ, Andersen NS, Maillard N, Nguyen S, Blaise D, Deconinck E, et al. Outcomes of Cord Blood Transplantation Using Reduced Intensity Conditioning for Chronic Lymphocytic Leukemia: a Study on Behalf of Eurocord and Cord Blood Committee of Celular Therapy and Immunobiology Working Party(CTIWP), Chronic Malignancies Working Pa. Biol Blood Marrow Transplant. 2015.
2016
Link CSibylle, Eugster A, Heidenreich F, Rücker-Braun E, Schmiedgen M, Oelschlägel U, Kühn D, Dietz S, Fuchs Y, Dahl A, et al. Abundant CMV reactive clonotypes in the CD8(+) T cell receptor alpha repertoire following allogeneic transplantation. Clin Exp Immunol. 2016.
2018
Teipel R, Oelschlägel U, Wetzko K, Schmiedgen M, Kramer M, Rücker-Braun E, Hölig K, von Bonin M, Heidrich K, Fuchs A, et al. Differences in cellular composition of peripheral blood stem cell grafts from healthy stem cell donors mobilized with either G-CSF alone or G-CSF and Plerixafor. Biol Blood Marrow Transplant. 2018.
Frick M, Chan W, Arends CMaximilian, Hablesreiter R, Halik A, Heuser M, Michonneau D, Blau O, Hoyer K, Christen F, et al. Role of Donor Clonal Hematopoiesis in Allogeneic Hematopoietic Stem-Cell Transplantation. J Clin Oncol. 2018:JCO2018792184.
2019
Kroschinsky F, Röllig D, Riemer B, Kramer M, Ordemann R, Schetelig J, Bornhäuser M, Ehninger G, Hänel M. Modified DHAP regimen in the salvage treatment of refractory or relapsed lymphomas. J Cancer Res Clin Oncol. 2019.
Beelen DWilhelm, Trenschel R, Stelljes M, Groth C, Masszi T, Reményi P, Wagner-Drouet E-M, Hauptrock B, Dreger P, Luft T, et al. Treosulfan or busulfan plus fludarabine as conditioning treatment before allogeneic haemopoietic stem cell transplantation for older patients with acute myeloid leukaemia or myelodysplastic syndrome (MC-FludT.14/L): a randomised, non-inferiority, phase 3 . Lancet Haematol. 2019.
2020
Schmidt AH, Sauter J, Baier DM, Daiss J, Keller A, Klussmeier A, Mengling T, Rall G, Riethmüller T, Schöfl G, et al. Immunogenetics in stem cell donor registry work: The DKMS example (Part 2). Int J Immunogenet. 2020.
Mengling T, Rall G, Bernas SN, Astreou N, Bochert S, Boelk T, Buk D, Burkard K, Endert D, Gnant K, et al. Stem cell donor registry activities during the COVID-19 pandemic: a field report by DKMS. Bone Marrow Transplant. 2020.
2021
Bernas SN, Baldauf H, Wendler S, Heidenreich F, Lange V, Hofmann JA, Sauter J, Schmidt AH, Schetelig J. CCR5Δ32 mutations do not determine COVID-19 disease course. Int J Infect Dis. 2021.
Story CMcIlwaine, Wang T, Bhatt VRaj, Battiwalla M, Badawy SM, Kamoun M, Gragert L, Brown V, Baxter-Lowe LAnn, Marsh SGe, et al. Genetics of HLA peptide presentation, and impact on outcomes in HLA-matched allo-HCT. Transplant Cell Ther. 2021.
2022
Bernas SN, Behrens GA, Baldauf H, Baier DM, Fischer H, Pruschke J, Heidenreich F, Ruhner K, Hofmann JA, Markert J, et al. Reanalysis of unclear CMV status results from buccal swab samples of potential stem cell donors is an efficient donor registry strategy. Transpl Immunol. 2022:101729.
2023
Weller JFrederic, Lengerke C, Finke J, Schetelig J, Platzbecker U, Einsele H, Schroeder T, Faul C, Stelljes M, Dreger P, et al. Allogeneic hematopoietic stem cell transplantation in patients aged 60-79 years in Germany (1998-2018): a registry study. Haematologica. 2023.
Nelde A, Schuster H, Heitmann JS, Bauer J, Maringer Y, Zwick M, Volkmer J-P, Chen JY, Stanger AMPaczulla, Lehmann A, et al. Immune Surveillance of Acute Myeloid Leukemia Is Mediated by HLA-Presented Antigens on Leukemia Progenitor Cells. Blood Cancer Discov. 2023:OF1-OF22.
Nagler A, Labopin M, Kröger N, Schroeder T, Gedde-Dahl T, Eder M, Franke G-N, Blau IWolfgang, Salmenniemi U, Socié G, et al. The role of anti-thymocyte globulin in allogeneic stem cell transplantation (HSCT) from HLA-matched unrelated donors (MUD) for secondary AML in remission: a study from the ALWP /EBMT. Bone Marrow Transplant. 2023.
Al-Sawaf O, Ligtvoet R, Robrecht S, Stumpf J, Fink A-M, Tausch E, Schneider C, Boettcher S, Mikusko M, Ritgen M, et al. Tislelizumab plus zanubrutinib for Richter transformation: the phase 2 RT1 trial. Nat Med. 2023.
Eckardt J-N, Röllig C, Metzeler K, Heisig P, Stasik S, Georgi J-A, Kroschinsky F, Stölzel F, Platzbecker U, Spiekermann K, et al. Unsupervised meta-clustering identifies risk clusters in acute myeloid leukemia based on clinical and genetic profiles. Commun Med (Lond). 2023;3(1):68.
2024
Schetelig J, Baldauf H, Heidenreich F, Hoogenboom JD, Spellman SR, Kulagin A, Schroeder T, Sengeloev H, Dreger P, Forcade E, et al. Donor genotype based outcome prediction after allogeneic stem cell transplantation: no land in sight. Front Immunol. 2024;15:1350470.
Sureda A, Carpenter PA, Bacigalupo A, Bhatt VRaj, De La Fuente J, Ho A, Kean L, Lee JWook, Sánchez-Ortega I, Savani BN, et al. Harmonizing definitions for hematopoietic recovery, graft rejection, graft failure, poor graft function, and donor chimerism in allogeneic hematopoietic cell transplantation: a report on behalf of the EBMT, ASTCT, CIBMTR, and APBMT. Bone Marrow Transplant. 2024.
Schmidt AH, Sauter J, Schetelig J, Neujahr E, Pingel J. Providing hematopoietic stem cell products from unrelated donors to the world: DKMS donor centers and DKMS Registry. Best Pract Res Clin Haematol. 2024;37(1):101541.
Stelljes M, Middeke JMoritz, Bug G, Wagner-Drouet E-M, Müller LP, Schmid C, Krause SW, Bethge W, Jost E, Platzbecker U, et al. Remission induction versus immediate allogeneic haematopoietic stem cell transplantation for patients with relapsed or poor responsive acute myeloid leukaemia (ASAP): a randomised, open-label, phase 3, non-inferiority trial. Lancet Haematol. 2024.
Schulz F, Jäger P, Tischer J, Fraccaroli A, Bug G, Hausmann A, Baermann B-N, Tressin P, Hoelscher A, Kasprzak A, et al. Smart Conditioning with Venetoclax-Enhanced Sequential FLAMSA + RIC in Patients with High-Risk Myeloid Malignancies. Cancers (Basel). 2024;16(3).